Logo

TVGN

Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc. • NASDAQ
$0.44 ▼ -8.27% (-0.04)
Market Cap $87.66 M
52w High $1.92
52w Low $0.38
Dividend Yield 0%
P/E -2.45
Volume 227.16K
Outstanding Shares 198.69M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $5.702M ▲ $-5.727M ▼ 0% $-0.03 ▲ $-5.637M ▼
Q2-2025 $0 $5.154M ▼ $-5.504M ▲ 0% $-0.031 ▲ $-5.175M ▲
Q1-2025 $0 $10.251M ▲ $-10.367M ▼ 0% $-0.065 ▼ $-10.237M ▼
Q4-2024 $0 $9.26M ▲ $-9.25M ▼ 0% $-0.052 ▼ $-9.325M ▼
Q3-2024 $0 $5.984M $-5.909M 0% $-0.035 $-5.77M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.037M ▲ $4.494M ▲ $12.318M ▼ $-7.824M ▲
Q2-2025 $685.229K ▼ $4.269M ▲ $13.754M ▲ $-9.485M ▼
Q1-2025 $1.975M ▲ $4.073M ▲ $11.793M ▲ $-7.72M ▼
Q4-2024 $1.283M ▼ $3.462M ▼ $10.136M ▼ $-6.674M ▼
Q3-2024 $2.331M $4.289M $10.48M $-6.19M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.727M ▼ $-3.65M ▼ $0 $4.001M ▲ $351.865K ▲ $-3.65M ▼
Q2-2025 $-5.504M ▲ $-3.19M ▲ $0 $1.9M ▼ $-1.29M ▼ $-3.19M ▲
Q1-2025 $-10.367M ▼ $-3.308M ▼ $0 $4M ▲ $691.937K ▲ $-3.308M ▼
Q4-2024 $-9.25M ▼ $-3.048M ▲ $0 $2M ▼ $-1.048M ▼ $-3.048M ▲
Q3-2024 $-5.884M $-3.805M $0 $5M $1.195M $-3.805M

Five-Year Company Overview

Income Statement

Income Statement Tevogen Bio is still a pure R&D story: it has no product revenue yet and only modest operating expenses, mainly from research and corporate overhead. Losses are currently small in absolute terms but will likely grow if the company scales trials and infrastructure. Profitability is a distant goal and will depend entirely on successfully bringing one or more therapies through clinical trials and into the market.

Balance Sheet

Balance Sheet The balance sheet is very light, with limited assets and virtually no reported cash by the latest period, and equity turning slightly negative. Earlier years showed some debt that has been reduced, but the company now looks capital‑constrained and highly reliant on external funding to continue operations and advance clinical programs. Overall financial resilience appears thin, which is typical but still risky for a young biotech at this stage.

Cash Flow

Cash Flow Cash flow reflects a standard early‑stage biotech pattern: money going out for operations and essentially nothing coming in. There is no meaningful investment in physical assets; spending is mostly on people, research, and overhead. The company’s ability to sustain these outflows will depend on new capital raises, partnerships, or other funding sources rather than internal cash generation for the foreseeable future.

Competitive Edge

Competitive Edge Competitively, Tevogen is trying to carve out a niche with an off‑the‑shelf, non‑gene‑edited T cell platform that aims to be more scalable, safer, and more affordable than many existing cell therapies. The focus on large patient populations, a strong cost story, and vertical integration could be differentiators. However, it competes in a crowded and rapidly evolving immunotherapy space with far larger, better funded players, so execution, proof of clinical benefit, and cost advantages will be critical to stand out.

Innovation and R&D

Innovation and R&D Innovation is the clear strength. The ExacTcell platform and the Tevogen.AI initiative together target more precise T cell therapies, faster target discovery, and more efficient manufacturing. Early clinical data for the lead COVID and Long COVID candidate appear promising on safety and activity, and the expansion into oncology and neurology broadens potential impact. The company controls its core intellectual property, which helps, but most assets are still early‑stage, so scientific and regulatory risk remain high.

Summary

Tevogen Bio is a very early‑stage, clinical biotech with a lean financial base, no current revenue, and small but recurring losses. Its value proposition rests almost entirely on the promise of its T cell and AI‑driven platforms, the ambition to deliver more accessible cell therapies, and a pipeline spanning infectious disease, oncology, and neurology. The opportunity is significant if the science translates into successful late‑stage trials and scalable manufacturing, but the company faces the usual high biotech risks: scientific uncertainty, regulatory hurdles, intense competition, and an ongoing need for external capital to fund its plans.

NEWS

November 14, 2025 · 2:32 PM UTC

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Read more

November 5, 2025 · 3:20 PM UTC

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Read more

November 3, 2025 · 2:45 PM UTC

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Read more

October 29, 2025 · 12:35 PM UTC

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Read more

October 15, 2025 · 3:50 PM UTC

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Read more